Cargando…
Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis
BACKGROUND: Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore the association of fatty acid synthase (FASN...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817350/ https://www.ncbi.nlm.nih.gov/pubmed/36604718 http://dx.doi.org/10.1186/s13046-022-02567-z |
_version_ | 1784864735583272960 |
---|---|
author | Li, Yan Yang, Wenjuan Zheng, Yuanyuan Dai, Weiqi Ji, Jie Wu, Liwei Cheng, Ziqi Zhang, Jie Li, Jingjing Xu, Xuanfu Wu, Jianye Yang, Mingwei Feng, Jiao Guo, Chuanyong |
author_facet | Li, Yan Yang, Wenjuan Zheng, Yuanyuan Dai, Weiqi Ji, Jie Wu, Liwei Cheng, Ziqi Zhang, Jie Li, Jingjing Xu, Xuanfu Wu, Jianye Yang, Mingwei Feng, Jiao Guo, Chuanyong |
author_sort | Li, Yan |
collection | PubMed |
description | BACKGROUND: Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore the association of fatty acid synthase (FASN) with sorafenib resistance via regulation of ferroptosis and provide a novel treatment strategy to overcome the sorafenib resistance of HCC patients. METHODS: Intracellular levels of lipid peroxides, glutathione, malondialdehyde, and Fe(2+) were measured as indicators of ferroptosis status. Biological information analyses, immunofluorescence assays, western blot assays, and co-immunoprecipitation analyses were conducted to elucidate the functions of FASN in HCC. Both in vitro and in vivo studies were conducted to examine the antitumor effects of the combination of orlistat and sorafenib and CalcuSyn software was used to calculate the combination index. RESULTS: Solute carrier family 7 member 11 (SLC7A11) was found to play an important role in mediating sorafenib resistance. The up-regulation of FASN antagonize of SLC7A11-mediated ferroptosis and thereby promoted sorafenib resistance. Mechanistically, FASN enhanced sorafenib-induced ferroptosis resistance by binding to hypoxia-inducible factor 1-alpha (HIF1α), promoting HIF1α nuclear translocation, inhibiting ubiquitination and proteasomal degradation of HIF1α, and subsequently enhancing transcription of SLC7A11. Orlistat, an inhibitor of FASN, with sorafenib had significant synergistic antitumor effects and reversed sorafenib resistance both in vitro and in vivo. CONCLUSION: Targeting the FASN/HIF1α/SLC7A11 pathway resensitized HCC cells to sorafenib. The combination of orlistat and sorafenib had superior synergistic antitumor effects in sorafenib-resistant HCC cells. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02567-z. |
format | Online Article Text |
id | pubmed-9817350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98173502023-01-07 Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis Li, Yan Yang, Wenjuan Zheng, Yuanyuan Dai, Weiqi Ji, Jie Wu, Liwei Cheng, Ziqi Zhang, Jie Li, Jingjing Xu, Xuanfu Wu, Jianye Yang, Mingwei Feng, Jiao Guo, Chuanyong J Exp Clin Cancer Res Research BACKGROUND: Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore the association of fatty acid synthase (FASN) with sorafenib resistance via regulation of ferroptosis and provide a novel treatment strategy to overcome the sorafenib resistance of HCC patients. METHODS: Intracellular levels of lipid peroxides, glutathione, malondialdehyde, and Fe(2+) were measured as indicators of ferroptosis status. Biological information analyses, immunofluorescence assays, western blot assays, and co-immunoprecipitation analyses were conducted to elucidate the functions of FASN in HCC. Both in vitro and in vivo studies were conducted to examine the antitumor effects of the combination of orlistat and sorafenib and CalcuSyn software was used to calculate the combination index. RESULTS: Solute carrier family 7 member 11 (SLC7A11) was found to play an important role in mediating sorafenib resistance. The up-regulation of FASN antagonize of SLC7A11-mediated ferroptosis and thereby promoted sorafenib resistance. Mechanistically, FASN enhanced sorafenib-induced ferroptosis resistance by binding to hypoxia-inducible factor 1-alpha (HIF1α), promoting HIF1α nuclear translocation, inhibiting ubiquitination and proteasomal degradation of HIF1α, and subsequently enhancing transcription of SLC7A11. Orlistat, an inhibitor of FASN, with sorafenib had significant synergistic antitumor effects and reversed sorafenib resistance both in vitro and in vivo. CONCLUSION: Targeting the FASN/HIF1α/SLC7A11 pathway resensitized HCC cells to sorafenib. The combination of orlistat and sorafenib had superior synergistic antitumor effects in sorafenib-resistant HCC cells. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02567-z. BioMed Central 2023-01-06 /pmc/articles/PMC9817350/ /pubmed/36604718 http://dx.doi.org/10.1186/s13046-022-02567-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Li, Yan Yang, Wenjuan Zheng, Yuanyuan Dai, Weiqi Ji, Jie Wu, Liwei Cheng, Ziqi Zhang, Jie Li, Jingjing Xu, Xuanfu Wu, Jianye Yang, Mingwei Feng, Jiao Guo, Chuanyong Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis |
title | Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis |
title_full | Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis |
title_fullStr | Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis |
title_full_unstemmed | Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis |
title_short | Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis |
title_sort | targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817350/ https://www.ncbi.nlm.nih.gov/pubmed/36604718 http://dx.doi.org/10.1186/s13046-022-02567-z |
work_keys_str_mv | AT liyan targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT yangwenjuan targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT zhengyuanyuan targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT daiweiqi targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT jijie targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT wuliwei targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT chengziqi targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT zhangjie targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT lijingjing targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT xuxuanfu targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT wujianye targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT yangmingwei targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT fengjiao targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis AT guochuanyong targetingfattyacidsynthasemodulatessensitivityofhepatocellularcarcinomatosorafenibviaferroptosis |